The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis

Current Cancer Drug Targets

Volumn 11, Issue 5, 2011, Pages 586-599

  Benbrook, D M ^a   Masamha, C P ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Akt; Apoptosis; Caveolin; Cyclin dependent kinase 2; FoxO transcription factors; Mammalian target of rapamycin; Phosphorylation; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; AFIMOXIFENE; ANTINEOPLASTIC AGENT; CAVEOLIN; CAVEOLIN 1; CYCLIN D1; DEATH RECEPTOR; DOCETAXEL; ETOPOSIDE; G PROTEIN COUPLED RECEPTOR; GLUCOSE 6 PHOSPHATASE; GLYCOGEN SYNTHASE KINASE 3BETA; LONIDAMINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METHOTREXATE; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SERINE; STAUROSPORINE; SURVIVIN; THREONINE; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ADENOVIRUS; AEROBIC METABOLISM; ANGIOGENESIS; APOPTOSIS; AUTOPHOSPHORYLATION; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CATALYSIS; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL MEMBRANE; CELL METABOLISM; CELL PERMEABILIZATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; COLONY FORMATION; CYTOPLASM; DIABETES MELLITUS; DRUG EFFICACY; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME REGULATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART VENTRICLE HYPERTROPHY; HYDROLYSIS; INSULIN BINDING; KIDNEY HYPERTROPHY; MITOCHONDRION; MUTAGENESIS; NEOPLASM; NONHUMAN; ONCOGENE C MYC; OXIDATION; OXIDATIVE STRESS; PROTECTION; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PRENYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RNA TRANSLATION; SERUM; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; UNINEPHRECTOMY; UPREGULATION;

EID: 79958106479     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911795655994     Document Type: Review

References (102)

1. Yaffe, M. B.; Leparc, G. G.; Lai, J.; Obata, T.; Volinia, S.; Cantley, L. C. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat. Biotech. 2001, 19(4), 348-353.
2. Bunney, T. D.; Katan, M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat. Rev. Cancer 2010, 10(5), 342-352.
3. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28(6) 1075-1083.
4. Shaw, R. J.; Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092), 424-430.
5. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M. D. Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer. Ann. Rev. Cell Devel. Biol. 2001, 17(1), 615-675.
6. Dong, L. Q.; Liu, F. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am. J. Physiol. Endocrinol. Metab. 2005, 289, E187-E196.
7. Masters, T. A.; Calleja, V.; Armoogum, D. A.; Marsh, R. J.; Applebee, C. J.; Laguerre, M.; Bain, A. J.; Larijani, B. Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells. Science Signaling [Electronic Resource] 2010, 3, (145), ra78.
8. Bayascas, J. R. PDK1: the major transducer of PI 3-kinase actions. Curr. Top. Microbiol. Immun. 2010, 346, 9-29.
9. Hresko, R. C.; Mueckler, M. mTOR.RICTOR is the Ser 473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 2005, 280, 40406-40416.
10. Steelman, L. S.; Stadelman, K. M.; Chappell, W. H.; Horn, S.; Bäsecke, J.; Cervello, M.; Nicoletti, F.; Libra, M.; F., S.; Martelli, A. M.; McCubrey, J. A. Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 2008, 12(9), 1139-1165.
11. Alessi, D. R.; Andjelkovic, M.; Caudwell, B. C., P.; Morrice, N.; Cohen, P.; Hemmings, B. A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15, 6541-6551.
12. Kitamura, T.; Ogawa, W.; Sakaue, H.; Hino, Y.; Kuroda, S.; Takata, M.; Matsumoto, M.; Maeda, T.; Konishi, H.; Kikkawa, U.; Kasuga, M. Requirement for activation of the serin-threonine kinase Akt (Protein Kinase B) in insuling stimulation of protein synthesis by not of glucose transport. Mol. Cell. Biol. 1998, 18(7), 3708-3717.
13. Kohn, A. D.; Summers, S. A.; Birnbaum, M. J.; Roth, R. A. Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 1996, 271, 31372-31378.
14. Leslie, N. R.; Bennett, D.; Lindsay, Y. E.; Stewart, H.; Gray, A.; Downes, C. P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22, 5501-5510.
15. Fedele, C. G.; Ooms, L. M.; Ho, M.; Vieusseux, J.; O'Toole, S. A.; Millar, E. K.; Lopez-Knowles, E.; Sriratana, A.; Gurung, R.; Baglietto, L.; Giles, G. G.; Bailey, C. G.; Rasko, J. E. J.; Shields, B. J.; Price, J. T.; Majerus, P. W.; Sutherland, R. L.; Tiganis, T.; McLean, C. A.; Mitchell, C. A. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Nat. Acad. Sci. USA 2011, 107(51), 22231-6.
16. Chan, T. O.; Tsichlis, P. N. PDK2: A complex tail in one Akt. Sci. STKE 2001, 2001(66), pe1-.
17. Adjelkovic, M.; Jakubowicz, T.; Cron, P.; Ming, X. F.; Han, J.-W.; Hemmings, B. A. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl. Acad. Sci. U S A 1996, 93(12), 5699-5704.
18. Miyamoto, S.; Purcell, N. H.; Smith, J. M.; Gao, T.; Whittaker, R.; Huang, K.; Castillo, R.; Glembotski, C. C.; Sussman, M. A.; Newton, A. C.; J., H. B. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ. Res. 2011, 107, 476-484.
19. Diehl, J. A.; Cheng, M.; Roussel, M. F.; Sherr, C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Develop. 1998, 12(22), 3499-511.
20. Cross, D. A.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378, 785-789.
21. Manning, B. D.; Cantley, L. C. AKT/PKB signaling: Navigating downstream. Cell 2007, 129(7), 1261-1274.
22. Maurer, U.; Charvet, C.; Wagman, A. S.; Dejardin, E.; Green, D. R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21(6), 749-760.
23. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96, 857-868.
24. Dijkers, P. F.; Medema, R. H.; Pals, C.; Banerji, L.; Thomas, N. S. B.; Lam, E. W. F.; Burgering, B. M. T.; Raaijmakers, J. A. M.; Lammers, J.-W. J.; Koenderman, L.; Coffer, P. J. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27KIP1. Mol. Cell. Biol. 2000, 20(24), 9138-9148.
25. Schmidt, M.; Fernandez de Mattos, S.; van der Horst, A.; Klompmaker, R.; Kops, G. J. P. L.; Lam, E. W. F.; Burgering, B. M. T.; Medema, R. H. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol. Cell. Biol. 2002, 22(22), 7842-7852.
26. Dijkers, P. F.; Medema, R. H.; Lammers, J. W.; Koenderman, L.; Coffer, P. J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 2000, 10, 1201-1204.
27. Nakae, J.; Kitamura, T.; Silver, D. L.; Accili, D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 2001, 108, 1359-1367.
28. Kops, G. J. P. L.; Dansen, T. B.; Polderman, P. E.; Saarloos, I.; Wirtz, K. W. A.; Coffer, P. J.; Huang, T.-T.; Bos, J. L.; Medema, R. H.; Burgering, B. M. T. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002, 419(6904), 316-321.
29. Singh, A.; Ye, M.; Bucur, O.; Zhu, S.; Tanya Santos, M.; Rabinovitz, I.; Wei, W.; Gao, D.; Hahn, W. C.; Khosravi-Far, R. Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Molecular Biology of the Cell 2010, 21(6), 1140-52.
30. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282(5392), 1318-21.
31. del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278, 687-689.
32. Loewith, R.; Jacinto, E.; Wullschleger, S.; Lorberg, A.; Crespo, J. L.; Bonenfant, D.; Oppliger, W.; Jenoe, P.; Hall, M. N. Two TOR complexes, only one of which Is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 2002, 10(3), 457-468.
33. Nave, B. T.; Ouwens, M.; Withers, D. J.; Alessi, D. R.; Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 1999, 344(Pt2), 427-431.
34. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4, 648-657.
35. Madrid, L. V.; Mayo, M. W.; Reuther, J. Y.; Baldwin, J., A.S. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-B through utilization of the IB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 2001, 276, 18934-18940.
36. Feng, B.; Cheng, S.; Hsia, C. Y.; King, L. B.; Monroe, J. G.; Liou, H.-C. NF-kappaB inducible genes BCL-X and cyclin E promote immature B-cell proliferation and survival. Cell. Immunol. 2004, 232(1-2), 9-20.
37. Ougolkov, A. V.; Bone, N. D.; Fernandez-Zapico, M. E.; Kay, N. E.; Billadeau, D. D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110(2), 735-42.
38. Dan, H. C.; Cooper, M. J.; Cogswell, P. C.; Duncan, J. A.; Ting, J. P. Y.; Baldwin, A. S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Devel. 2008, 22(11), 1490-500.
39. Meric-Bernstam, F.; Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27, 2278-2287.
40. Holz, M. K.; Ballif, B. A.; Gygi, S. P.; Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123, 569-580.
41. Hara, K.; Yonezawa, K.; Kozlowski, M. T.; Sugimoto, T.; Andrabi, K.; Weng, q.-P.; Kasuga, M.; Nishimoto, I.; Avruc, J. Regulation of eIF-4E BP1 Phosphorylation by mTOR. J. Biol. Chem. 1997, 272, 26457-26463.
42. Feigenblum, D.; Schneider, R. J. Cap-binding protein (eukaryotic initiation factor 4E) and 4E-inactivating protein BP-1 independently regulate cap-dependent translation. Mol. Cell. Biol. 1996, 10, 5450-5457.
43. Graff, J. R.; Konicek, B. W.; Vincent, T. M.; Lynch, R. L.; Monteith, D.; Weir, S. N.; Schwier, P.; Capen, A.; Goode, R. L.; Dowless, M. S.; Chen, Y.; Zhang, H.; Sissons, S.; Cox, K.; McNulty, A. M.; Parsons, S. H.; Wang, T.; Sams, L.; Geeganage, S.; Douglass, L. E.; Neubauer, B. L.; Dean, N. M.; Blanchard, K.; Shou, J.; Stancato, L. F.; Carter, J. H.; Marcusson, E. G. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 2007, 117(9), 2638-2648.
44. Jefferies, H. B.; Reinhard, C.; Kozma, S. C.; Thomas, G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4441-4445.
45. Jefferies, H. B.; Fumagalli, S.; Dennis, P. B.; Reinhard, C.; Pearson, R. B.; G., T. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997, 16, 3693-3704.
46. Ruvinsky, I.; Sharon, N.; Lerer, T.; Cohen, H.; Stolovich-Rain, M.; Nir, T.; Dor, Y.; Zisman, P.; Meyuhas, O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 2005, 19, 2199-2211.
47. Stolovich, M.; Tang, H.; Hornstein, E.; Levy, G.; Cohen, R.; Bae, S. S.; Birnbaum, M. J.; Meyuhas, O. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the PI3-kinase-mediated pathway, but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell. Biol. 2002, 22, 8101-8113.
48. McMullen, J. R.; Shioi, T.; Zhang, L.; Tarnavski, O.; Sherwood, M. C.; Dorfman, A. L.; Longnus, S.; Pende, M.; Martin, K. A.; Blenis, J.; Thomas, G.; Izumo, S. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Biol. Cell 2004, 24, 6231-6240.
49. Chen, J.-K.; Chen, J.; Thomas, G.; Kozma, S. C.; Harris, R. C. S6 kinase 1 knockout inhibits uninephrectomy-or diabetes-induced renal hypertrophy. Am. J. Physiol.-Renal Physiol. 2009, 297(3), F585-93.
50. Hsieh, A. C.; Costa, M.; Zollo, O.; Davis, C.; Feldman, M. E.; Testa, J. R.; Meyuhas, O.; Shokat, K. M.; Ruggero, D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17, 249-261.
51. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8, 179-183.
52. McDonald, P. C.; Oloumi, A.; Mills, J.; Dobreva, I.; Maidan, M.; Gray, V.; Wederell, E. D.; Bally, M. B.; Foster, L. J.; Dedhar, S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res. 2008, 68(6), 1618-1624.
53. Han, E. K. H.; Leverson, J. D.; McGonigal, T.; Shah, O. J.; Woods, K. W.; Hunter, T.; Giranda, V. L.; Luo, Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007, 26(38), 5655-5661.
54. Tang, D.; Okada, H.; Ruland, J.; Liu, L.; Stambolic, V.; Mak, T. W.; Ingram, A. J. Akt Is activated in response to an apoptotic signal. J. Biol. Chem. 2001, 276, 30461-30466.
55. Coloff, J. L.; Mason, E. F.; Altman, B. J.; Gerriets, V. A.; Liu, T.; Nichols, A. N.; Zhao, Y.; Wofford, J. A.; Jacobs, S. R.; Ilkayeva, O.; Garrison, S. P.; Zambetti, G. P.; Rathmell, J. C. Akt Requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J. Biol. Chem. 2011, 286(7), 5921-5933.
56. van Gorp, A. G. M.; Pomeranz, K. M.; Birkenkamp, K. U.; Hui, R. C.-H.; Lam, E. W.-F.; Coffer, P. J. Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation Cancer Res. 2006, 66, 10760-10769.
57. Plas, D. R.; Talapatra, S.; Edinger, A. L.; Rathmell, J. C.; Thompson, C. B. Akt and Bcl-xL promote growth factorindependent survival through distinct effects on mitochondrial physiology. J. Biol. Chem. 2001, 276(15), 12041-8.
58. Nogueira, V.; Park, Y.; Chen, C. C.; Xu, P. Z.; Chen, M. L.; Tonic, I.; Unterman, T.; Hay, N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14, 458-470.
59. Hileman, E. O.; Liu, J.; Albitar, M.; Keating, M. J.; Huang, P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 2004, 53, 209-219.
60. Fulda, S.; Debatin, K.-M. Exploiting death receptor signaling pathways for tumor therapy. Biochimica et Biophysica Acta 2004, 1705(1), 27-41.
61. Lu, B.; Wang, L.; Stehlik, C.; Medan, D.; Huang, C.; Hu, S.; Chen, F.; Shi, X.; Rojanasakul, Y. Phosphatidylinositol 3-Kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells. J. Immunol. 2006, 176, 6785-6793.
62. Suhara, T.; Mano, T.; Oliveira, B. E.; Walsh, K. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICEinhibitory protein (FLIP). Circ. Res. 2001, 89, 13-19.
63. Lee, S.-M.; Lee, C.-T.; Kim, Y. W.; Han, S. K.; Shim, Y.-S.; Yoo, C.-G. Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett. 2006, 242, (2), 231-238.
64. Szlosarek, P. W.; Balkwill, F. R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003, 4(9), 565-573.
65. Krajewska, W. M.; Maslowska, I. Caveolins: structure and function in signal transduction. Cell. Mol. Biol. Lett. 2004, 9(2), 195-220.
66. Yu, W.; Cassara, J.; Weller, P. F. Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells. Blood 2000, 95, 1078-1108.
67. Tamaskar, I.; Zhou, M. Clinical implications of caveolins in malignancy and their potential as therapeutic targets. Curr. Oncol. Rep. 2008, 10(2), 101-106.
68. Ono, K.; Iwanaga, Y.; Hirayama, M.; Kawamura, T.; Sowa, N.; Hasegawa, K. Contribution of caveolin-1(alpha) and Akt to TNF-(alpha)-induced cell death. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287, L201-L204.
69. Shack, S.; Wang, X. T.; Kokkonen, G. C.; Gorospe, M.; Longo, D. L.; Holbrook, N. J. Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol. Cell. Biol. 2003, 23, 2407-2414.
70. Zundel, W.; Giaccia, A. Inhibition of the antiapoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev. 1998, 12, 1941-1946.
71. Maddika, S.; Ande, S. R.; Wiechec, E.; Hansen, L. L.; Wesselborg, S.; Los, M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J. Cell Sci. 2008, 121(Pt 7), 979-988.
72. Poon, I. K.; Oro, C.; Dias, M. M.; Zhang, J.; Jans, D. A. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005, 65, 7059-7064.
73. Maddika, S.; Bay, G. H.; Kroczak, T. J.; Ande, S. R.; Maddika, S.; Wiechec, E.; Gibson, S. B.; Los, M. Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptininduced cell death. Cell. Prolif. 2007, 40, 835-848.
74. Maddika, S.; Panigrahi, S.; Wiechec, E.; Wesselborg, S.; Fischer, U.; Schulze-Osthoff, K.; Los, M. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol. Cell. Biol. 2009, 29, 1235-1248.
75. Badve, S.; Collins, N. R.; Bhat-Nakshatri, P.; Turbin, D.; Leung, S.; Thorat, M.; Dunn, S. E.; Geistlinger, T. R.; Carroll, J. S.; Brown, M.; Bose, S.; Teitell, M. A.; Nakshatri, H. Subcellular localization of activated AKT in estrogen receptor-and progesterone receptor-expressing breast cancers: potential clinical implications. Am. J. Path. 2010, 176(5), 2139-2149.
76. Andrabi, S.; Gjoerup, O. V.; Kean, J. A.; Roberts, T. M.; Schaffhausen, B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc. Natl. Acad. Sci. USA 2007, 104, 19011-19016.
77. Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S.; Jung, S. Y.; Huang, Q.; Qin, J.; Su, B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127, 125-137.
78. Kuo, Y. C.; Huang, K. Y.; Yang, C. H.; Yang, Y. S.; Lee, W. Y.; Chiang, C. W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55- regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 2008, 283, 1882-1892.
79. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt//PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24(50), 7482-7492.
80. Granville, C.; Memmott, R. M.; Gills, J. J.; Dennis, P. A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of Rapamycin pathway. Clin. Cancer Res. 2006, 12, 679-689.
81. Dillon, R. L.; Marcotte, R.; Hennessy, B. T.; Woodgett, J. R.; Mills, G. B.; Muller, W. J. Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 2009, 69(12), 5057-5064.
82. Ermoian, R. P.; Furniss, C. S.; Lamborn, K. R.; Basila, D.; Berger, M. S.; Gottschalk, A. R.; Nicholas, M. K.; Stokoe, D.; Haas-Kogan, D. A. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 2002, 8(5), 1100-1106.
83. Dai, D. L.; Martinka, M.; Li, G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J. Clin. Oncol. 2005, 23(7), 1473-1482.
84. Nakanishi, K.; Sakamoto, M.; Yamasaki, S.; Todo, S.; Hirohashi, S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103, 307-312.
85. Tamburini, J.; Elie, C.; Bardet, V.; Chapuis, N.; Park, S.; Broet, P.; Cornillet-Lefebvre, P.; Lioure, B.; Ugo, V.; Blanchet, O.; Ifrah, N.; Witz, F.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007, 110(3), 1025-1028.
86. Ohta, T.; Isobe, M.; Takahashi, T.; Saitoh-Sekiguchi, M.; Motoyama, T.; Kurachi, H. The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer Res. 2009, 29(11), 4639-47.
87. Seon Young, N. A. M.; Hye Seung, L. E. E.; Gyung-Ah, J.; Jimi, C.; Sung Jin, C. H. O.; Min Kyu, K. I. M.; Woo Ho, K. I. M.; Byung Lan, L. E. E. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. Apmis 2003, 111, (12), 1105-1113.
88. Gonzalez, E.; McGraw, T. E. The Akt kinases. Isoform specificity in metabolism and cancer. Cell Cycle 2009, 8(16), 2502-2508.
89. Ericson, K.; Gan, C.; Cheong, I.; Rago, C.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Huso, D. L.; Vogelstein, B.; Papadopoulos, N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.[Erratum appears in Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6551]. Proc. Nat. Acad. Sci. USA 2010, 107(6), 2598-603.
90. Yang, W.; Ju, J.-h.; Lee, K.-m.; Shin, I. Akt isoform-specific inhibition of MDA-MB-231 cell proliferation. Cell. Signal. 2011, 23(1), 19-26.
91. Carpten, J. D.; Faber, A. L.; Horn, C.; Donoho, G. P.; Briggs, S. L.; Robbins, C. M.; Hostetter, G.; Boguslawski, S.; Moses, T. Y.; Savage, S.; Uhlik, M.; Lin, A.; Du, J.; Qian, Y. W.; Zeckner, D. J.; Tucker-Kellogg, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M. H.; Blanchard, K. L.; Thomas, J. E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448(7152), 439-444.
92. Dos, D. S.; Ali, S. M.; Kim, D.-H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14(14), 1296-1302.
93. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307(5712), 1098-1101.
94. Kwiatkowski, D. J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 2003, 67, 87-96.
95. Chandarlapaty, S.; Sawai, A.; Scaltriti, M.; Rodrik-Outmezguine, V.; Grbovic-Huezo, O.; Serra, V.; Majumder, P. K.; Baselga, J.; Rosen, N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19(1), 58-71.
96. Dobashi, Y.; Suzuki, S.; Kimura, M.; Matsubara, H.; Tsubochi, H.; Imoto, I.; Ooi, A. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum. Pathol. 2011, 42(2), 214-26.
97. Sozopoulos, E.; Litsiou, H.; Voutsinas, G.; Mitsiades, N.; Anagnostakis, N.; Tseva, T.; Patsouris, E.; Tseleni-Balafouta, S. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocrine Pathol. 2010, 21(2), 90-100.
98. Karra, L.; Shushan, A.; Ben-Meir, A.; Rojansky, N.; Klein, B. Y.; Shveiky, D.; Levitzki, R.; Ben-Bassat, H. Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fert. Steril. 2011, 93(8), 2646-2651.
99. Wang, Y.; Ozawa, A.; Zaman, S.; Prasad, N. B.; Chandrasekharappa, S. C.; Agarwal, S. K.; Marx, S. J. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Research 2011, 71(2), 371-82.
100. Yang, N.-Y.; Fernandez, C.; Richter, M.; Xiao, Z.; Valencia, F.; Tice, D. A.; Pasquale, E. B. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell. Signal. 2011, 23(1), 201-212.
101. Freudlsperger, C.; Burnett, J. R.; Friedman, J. A.; Kannabiran, V. R.; Chen, Z.; Van Waes, C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Exp. Op. Therap. Targets 2011, 15(1), 63-74.
102. Berns, K.; Horlings, H. M.; Hennessy, B. T.; Madiredjo, M.; Hijmans, E. M.; Beelen, K.; Linn, S. C.; Gonzalez-Angulo, A. M.; Stemke-Hale, K.; Hauptmann, M.; Beijersbergen, R. L.; Mills, G. B.; van de Vijver, M. J.; Bernards, R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4), 395-402.